Search research articles
Contact Us
Filters
Showing results (341-350 of 411) with videos related to
Page
of 42
Sort By:
Anaesthesia and Intensive Care
|
March 15, 2003
The efficacy and cost-effectiveness of prophylactic 5-hydroxytryptamine3 receptor antagonists: tropisetron, ondansetron and dolasetron
M J Paech, M W M Rucklidge, S L Banks, et al.
Hernia : the Journal of Hernias and Abdominal Wall Surgery
|
March 21, 2022
BMI: does it predict the need for component separation?
J R Smith, R Kyriakakis, M P Pressler, et al.
The American Journal of Clinical Nutrition
|
February 1, 1996
Rapid modulation of lung and liver macrophage phospholipid fatty acids in endotoxemic rats by continuous enteral feeding with n-3 and gamma-linolenic fatty acids
J D Palombo, S J DeMichele, E E Lydon, et al.
Diabetes Care
|
June 19, 2024
Efficacy and Safety of LX9211 for Relief of Diabetic Peripheral Neuropathic Pain (RELIEF-DPN 1): Results of a Double-Blind, Randomized, Placebo-Controlled, Proof-of-Concept Study
Rodica Pop-Busui, Anand Patel, Christine Nai-Mei Sang, et al.
ACS Pharmacology & Translational Science
|
November 21, 2022
Preclinical Characterization and Development on NAQ as a Mu Opioid Receptor Partial Agonist for Opioid Use Disorder Treatment
Piyusha P Pagare, Samuel Obeng, Boshi Huang, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
January 14, 2021
Manipulating Pharmacodynamic Efficacy with Agonist + Antagonist Mixtures: In Vitro and In Vivo Studies with Opioids and Cannabinoids
D E Selley, M L Banks, C M Diester, et al.
Molecular Pharmaceutics
|
June 8, 2026
Synthesis and Preliminary Evaluation of the <sup>211</sup>At-Labeled PARP Inhibitor [<sup>211</sup>At]Talazoparib as a Targeted Alpha-Particle Emitting Therapeutic
Yongxiang Zheng, Deyu Kong, Truc T Huynh, et al.
Experimental and Clinical Psychopharmacology
|
May 7, 2014
Abuse-related effects of dual dopamine/serotonin releasers with varying potency to release norepinephrine in male rats and rhesus monkeys
Matthew L Banks, Clayton T Bauer, Bruce E Blough, et al.
Nature
|
June 2, 1998
Role of a p53 polymorphism in the development of human papillomavirus-associated cancer
A Storey, M Thomas, A Kalita, et al.
Journal of Medicinal Chemistry
|
March 19, 2004
Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening
Thomas A Halgren, Robert B Murphy, Richard A Friesner, et al.
Page
of 42
Search research articles
Search
Showing results (341-350 of 411) with videos related to
Sort By:
Page
of 42
Anaesthesia and Intensive Care
|
March 15, 2003
The efficacy and cost-effectiveness of prophylactic 5-hydroxytryptamine3 receptor antagonists: tropisetron, ondansetron and dolasetron
M J Paech, M W M Rucklidge, S L Banks, et al.
Hernia : the Journal of Hernias and Abdominal Wall Surgery
|
March 21, 2022
BMI: does it predict the need for component separation?
J R Smith, R Kyriakakis, M P Pressler, et al.
The American Journal of Clinical Nutrition
|
February 1, 1996
Rapid modulation of lung and liver macrophage phospholipid fatty acids in endotoxemic rats by continuous enteral feeding with n-3 and gamma-linolenic fatty acids
J D Palombo, S J DeMichele, E E Lydon, et al.
Diabetes Care
|
June 19, 2024
Efficacy and Safety of LX9211 for Relief of Diabetic Peripheral Neuropathic Pain (RELIEF-DPN 1): Results of a Double-Blind, Randomized, Placebo-Controlled, Proof-of-Concept Study
Rodica Pop-Busui, Anand Patel, Christine Nai-Mei Sang, et al.
ACS Pharmacology & Translational Science
|
November 21, 2022
Preclinical Characterization and Development on NAQ as a Mu Opioid Receptor Partial Agonist for Opioid Use Disorder Treatment
Piyusha P Pagare, Samuel Obeng, Boshi Huang, et al.
The Journal of Pharmacology and Experimental Therapeutics
|
January 14, 2021
Manipulating Pharmacodynamic Efficacy with Agonist + Antagonist Mixtures: In Vitro and In Vivo Studies with Opioids and Cannabinoids
D E Selley, M L Banks, C M Diester, et al.
Molecular Pharmaceutics
|
June 8, 2026
Synthesis and Preliminary Evaluation of the <sup>211</sup>At-Labeled PARP Inhibitor [<sup>211</sup>At]Talazoparib as a Targeted Alpha-Particle Emitting Therapeutic
Yongxiang Zheng, Deyu Kong, Truc T Huynh, et al.
Experimental and Clinical Psychopharmacology
|
May 7, 2014
Abuse-related effects of dual dopamine/serotonin releasers with varying potency to release norepinephrine in male rats and rhesus monkeys
Matthew L Banks, Clayton T Bauer, Bruce E Blough, et al.
Nature
|
June 2, 1998
Role of a p53 polymorphism in the development of human papillomavirus-associated cancer
A Storey, M Thomas, A Kalita, et al.
Journal of Medicinal Chemistry
|
March 19, 2004
Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening
Thomas A Halgren, Robert B Murphy, Richard A Friesner, et al.
Page
of 42